Comparative Pharmacology
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CHILDREN S CLARITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE versus CHILDREN S CLARITIN.
BROMODIPHENHYDRAMINE HYDROCHLORIDE AND CODEINE PHOSPHATE vs CHILDREN'S CLARITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bromodiphenhydramine hydrochloride is a first-generation antihistamine that antagonizes histamine H1 receptors, reducing allergic symptoms. Codeine phosphate is an opioid agonist at mu-opioid receptors, producing analgesia and antitussive effects. Combination provides enhanced cough suppression.
Loratadine is a long-acting second-generation antihistamine that selectively antagonizes peripheral histamine H1 receptors, thereby inhibiting the effects of histamine released from mast cells and basophils, reducing allergic symptoms.
5 mL of oral solution (containing bromodiphenhydramine hydrochloride 12.5 mg and codeine phosphate 10 mg) every 4-6 hours as needed; maximum 4 doses in 24 hours.
10 mg orally once daily
None Documented
None Documented
Codeine: 2.5-3.5 h (adults), prolonged in hepatic impairment. Diphenhydramine: 4-8 h (adults), extended in elderly.
The terminal elimination half-life of loratadine is 8-14 hours (mean 11 hours) in healthy adults; for the active metabolite descarboethoxyloratadine, half-life is 17-24 hours (mean 20 hours). This supports once-daily dosing.
Renal: 70-80% as metabolites (codeine ~10% unchanged; diphenhydramine <5% unchanged). Biliary/fecal: 20-30%.
Loratadine is primarily eliminated via hepatic metabolism, with approximately 80% of the dose excreted as metabolites in urine (40%) and feces (40%). Less than 1% is excreted unchanged in urine.
Category A/B
Category C
Antihistamine
Antihistamine